Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...
Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...
In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...
Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes. Now is an exciting time to be a ...
Genentech reveals five-year data showing Susvimo effectively maintains vision in wet AMD patients with fewer injections, offering a promising treatment alternative. “The long-term results reinforce ...
Nimesh A. Patel, MD, FASRS, from Mass Eye and Ear Hospital and Boston Children's Hospital presented a real-world study using the Vestrum database to examine usage trends for pegcetacoplan and ...
Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...
Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination. Topcon Healthcare, Inc, announced it has ...
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...
Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025. To strengthen Opus Genetics’ gene therapy program ...
The triad of inflammation, neuropathy, and vasculopathy plays a key role in the development and progression of diabetic retinopathy (DR). Dr. Varun Chaudhary and Dr. Patrick Bussfeld, discuss how ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback